Apart from CML LSCs, the same strategy might be applicable for targeting LSCs in AML patients with FLT3-ITD mutation and Philadelphia positive acute lymphoblastic leukemia that express CD26 [38,42]. This evidence concerns the gene FLT3 and acute myeloid leukemia.